These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6538845)

  • 21. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
    Nomura Y; Komori T; Okuda S; Segawa T
    Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.
    Fuller RW; Perry KW
    Biochem Pharmacol; 1982 Jun; 31(12):2199-200. PubMed ID: 7115441
    [No Abstract]   [Full Text] [Related]  

  • 23. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine.
    Agut J; Coviella IL; Wurtman RJ
    Neuropharmacology; 1984 Dec; 23(12A):1403-6. PubMed ID: 6543245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
    de Graaf CJ; Korf J
    Psychopharmacology (Berl); 1986; 90(1):54-7. PubMed ID: 3094062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypophysectomy reduces the haloperidol-induced changes in striatal dopamine receptor density.
    Hruska RE; Pitman KT
    Eur J Pharmacol; 1982 Nov; 85(2):201-5. PubMed ID: 7151867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease in rat striatal acetylcholine levels by some direct- and indirect-acting dopaminergic antagonists.
    Consolo S; Ladinsky H; Bianchi S
    Eur J Pharmacol; 1975; 33(2):345-51. PubMed ID: 1183479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the l isomer of fenfluramine on dopamine mechanisms in rat brain: further studies.
    Invernizzi R; Bertorelli R; Consolo S; Garattini S; Samanin R
    Eur J Pharmacol; 1989 May; 164(2):241-8. PubMed ID: 2759175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced effect of haloperidol and apomorphine after hypophysectomy: pharmacokinetic considerations.
    Lloyd KG; Bianchetti G; Worms P; Morselli PL
    J Pharm Pharmacol; 1983 Mar; 35(3):166-9. PubMed ID: 6132974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
    Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of moxestrol on haloperidol-induced changes in striatal acetylcholine levels and dopamine turn-over.
    Euvrard C; Labrie F; Boissier JR
    Commun Psychopharmacol; 1979; 3(5):329-34. PubMed ID: 548211
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of estradiol and haloperidol on hypophysectomized rat brain dopamine receptors.
    Di Paolo T; Daigle M; Labrie F
    Psychoneuroendocrinology; 1984; 9(4):399-404. PubMed ID: 6514934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ontogeny of tolerance to haloperidol: behavioral and biochemical measures.
    Coyle S; Napier TC; Breese GR
    Brain Res; 1985 Nov; 355(1):27-38. PubMed ID: 4075104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic mediation of beta-endorphin-induced catalepsy.
    Van Loon GR; Kim C
    Res Commun Chem Pathol Pharmacol; 1978 Jul; 21(1):37-44. PubMed ID: 567367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional supersensitivity of the hippocampal dopaminergic system after prolonged treatment with haloperidol.
    Bijak M; Smiałowski A
    Pharmacol Biochem Behav; 1989 Jan; 32(1):95-9. PubMed ID: 2567526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol.
    Umeda Y; Sumi T
    Eur J Pharmacol; 1990 Nov; 191(2):149-55. PubMed ID: 2086236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment.
    Vonvoigtlander PF; Losey EG; Triezenberg HJ
    J Pharmacol Exp Ther; 1975 Apr; 193(1):88-94. PubMed ID: 166158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigations into the relationship between the dopaminergic system and ascorbic acid in rat striatum.
    Desole MS; Miele M; Enrico P; Esposito G; Fresu L; De Natale G; Miele E
    Neurosci Lett; 1991 Jun; 127(1):34-8. PubMed ID: 1881615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of ceruletide on haloperidol-induced catalepsy in rats.
    Ibii N; Ikeda M; Takahara Y; Eigyo M; Akiyoshi T; Matsushita A
    Peptides; 1989; 10(4):779-83. PubMed ID: 2587420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.